#AntiviralTech

VERAS enables real-time viral detection & antiviral action in live cells, boosting virology research & mRNA medicine potential. #ViralSensing #AntiviralTech
Details:doi.org/10.1016/j.bidere.2025.100040

Bacteria That Heal from the Inside Out What if your medicine grew inside you? Scientists have engineered probiotic bacteria to deliver vaccines and antiviral therapies directly from your gut—no needles required.

Your next vaccine might not be an injection. It could be a probiotic that delivers antiviral protection from inside your gut. #OralVaccine #ProbioticTherapy #AntiviralTech

Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV | Nature Communications Targeting host proteins that are crucial for viral replication offers a promising antiviral strategy. We have designed and characterised antiviral PROteolysis TArgeting Chimeras (PROTACs) targeting the human protein cyclophilin A (CypA), a host cofactor for unrelated viruses including human immunodeficiency virus (HIV) and hepatitis C virus (HCV). The PROTAC warheads are based on fully synthetic macrocycles derived from sanglifehrin A, which are structurally different from the classical Cyp inhibitor, cyclosporine A. Our Cyp-PROTACs decrease CypA levels in cell lines and primary human cells and have high specificity for CypA confirmed by proteomics experiments. Critically, CypA degradation facilitates improved antiviral activity against HIV-1 in primary human CD4+ T cells compared to the non-PROTAC parental inhibitor, at limiting inhibitor concentrations. Similarly, we observe antiviral activity against HCV replicon in a hepatoma cell line. We propose that CypA-targeting PROTACs inhibi

Innovative PROTACs with macrocycle warheads selectively degrade cyclophilin A, inhibiting HIV-1 and HCV. Game-changer for targeting host proteins! #AntiviralTech PMID:39929804, Nat Commun 2025, @NatureComms https://doi.org/10.1038/s41467-025-56317-8 #Medsky 🧪